SCHEMBL4716013

SCHEMBL4716013

O=C(O)c1cc(S(=O)(=O)N2CCCCC2)c(F)cc1Cl

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.76
KMT2A Q03164 4/20 0.76
LMNA P02545 2/20 0.76
ALDH1A1 P00352 1/20 0.76
EPHX2 P34913 1/20 0.66
TSHR P16473 2/20 0.58
CYP3A4 P08684 1/20 0.57
TDP1 Q9NUW8 2/20 0.55
MCL1 Q07820 1/20 0.53
TP53 P04637 3/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 1/20 0.49
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ENPP2 Q13822 1/20 0.47
ALOX15 P16050 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12674484 0.99 MEN1 (0.74) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL11167834 0.89 MEN1 (0.76) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL4716285 0.87 MEN1 (1.00) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL4716208 0.87 MEN1 (1.00) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL3528323 0.86 ENPP2 (0.58) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL4760580 0.85 MEN1 (0.97) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL4761472 0.85 MEN1 (0.91) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL12675015 0.80 MEN1 (0.72) MEN1KMT2ALMNAALDH1A1EPHX2
SCHEMBL11169924 0.79 CYP3A4 (0.59) MEN1KMT2ALMNAALDH1A1TSHR
SCHEMBL4714390 0.78 KMT2A (0.48) MEN1KMT2ALMNAALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
EP-1615904-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS AstraZeneca AB (SE) 2006-01-18 EP disclosed
WO-2004092135-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA (SE) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 MEN1 4633/4885KMT2A 3726/4885LMNA 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.